ROCKVILLE, Md., Oct. 22 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. announced today that it will present five posters on the pharmacogenetics of iloperidone at the 57th American Society of Human Genetics (ASHG) annual meeting to be held in San Diego, CA, from October 23 through October 27, 2007. This announcement follows the submission of the NDA filing for iloperidone on September 27, 2007. Iloperidone is an investigational atypical antipsychotic for the treatment of schizophrenia.
The following posters will be presented on Thursday, October 25, 2007, from 4:30 p.m. to 6:30 p.m. PDT, at the San Diego Convention Center.
POSTER 1035 - Whole Genome Association Study Identifies Polymorphisms in the NPAS3 Gene Associated with Enhanced Response to Iloperidone Treatment in Patients with Schizophrenia POSTER 1036 - Pharmacogenetic Study of Iloperidone Treatment in Patients with Schizophrenia Identifies Markers Associated with Efficacy POSTER 1037 - Pharmacogenetic Analysis Shows Differences in Markers Associated with Response Between Two Atypical Antipsychotics, Iloperidone and Ziprasidone, in the Treatment of Patients with Schizophrenia POSTER 1039 - Whole Genome Association Study Identifies Polymorphisms in the CERKL Gene Associated with QT Prolongation during Iloperidone Treatment of Patients with Schizophrenia POSTER 1040 - Single-Nucleotide Polymorphisms in the CYP2D6 Gene Are Correlated with Iloperidone Drug Exposure Levels, Affecting the Degree of QTc Prolongation Associated with Iloperidone Treatment About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company with a focus on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. In addition to iloperidone, Vanda is developing VEC- 162, a compound for the treatment of sleep and mood disorders which is currently in Phase III for sleep disorders. Vanda's third product candidate in clinical development, VSF-173, is currently in a Phase II trial for the treatment of excessive sleepiness. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com/.
Note Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for its product candidates. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of Vanda's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, a lack of acceptance of Vanda's product candidates in the marketplace, a failure of the company to become or remain profitable, Vanda's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's report on Form 10-Q for the quarter ended June 30, 2007 (File No. 000-51863). No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
